Search by Drug Name or NDC

    NDC 00069-0238-01 Ruxience 100 mg/10mL Details

    Ruxience 100 mg/10mL

    Ruxience is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is RITUXIMAB.

    Product Information

    NDC 00069-0238
    Product ID 0069-0238_7b46204f-1661-40a2-8926-3811582bebe0
    Associated GPIs 21351860602020
    GCN Sequence Number 080059
    GCN Sequence Number Description rituximab-pvvr VIAL 10 MG/ML INTRAVEN
    HIC3 Z2W
    HIC3 Description ANTI-CD20 (B LYMPHOCYTE) MONOCLONAL ANTIBODY
    GCN 46734
    HICL Sequence Number 045899
    HICL Sequence Number Description RITUXIMAB-PVVR
    Brand/Generic Brand
    Proprietary Name Ruxience
    Proprietary Name Suffix n/a
    Non-Proprietary Name rituximab-pvvr
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 100
    Active Ingredient Units mg/10mL
    Substance Name RITUXIMAB
    Labeler Name Pfizer Laboratories Div Pfizer Inc
    Pharmaceutical Class CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761103
    Listing Certified Through 2025-12-31

    Package

    NDC 00069-0238-01 (00069023801)

    NDC Package Code 0069-0238-01
    Billing NDC 00069023801
    Package 1 VIAL, SINGLE-USE in 1 CARTON (0069-0238-01) / 10 mL in 1 VIAL, SINGLE-USE
    Marketing Start Date 2020-01-23
    NDC Exclude Flag N
    Pricing Information N/A